Microvascular perturbations in rats receiving the maximum tolerated dose of methotrexate or its major metabolite 7-hydroxymethotrexate.
Methotrexate (MTX) is a clinically important cytostatic antifolate. The study describes the acute effects of maximum tolerated doses of MTX or its major metabolite 7-hydroxymethotrexate (7-OH-MTX) on the ultrastructure of rat liver and kidneys. The ultrastructural changes in rats receiving MTX or 7-OH-MTX were, in principle, indistinguishable and their severity and extension increased with time of survival or doses of medication. All lesions were focal, microvascular, or parenchymal. Microvascular changes were more severe in nature when blood cells were present. The endothelial cells were swollen with loss of pinocytotic vesicles, their luminal plasma membrane formed blebs or were disrupted. Partly detached endothelial cells or deendothelialized areas, various types of white blood cells, in particular, neutrophil granulocytes, were observed in the microcirculation. Single platelets or small platelet aggregates were found either in the lumen or adhering to deendothelialized areas of injured endothelial cells. Hepatocytes exhibited steatosis, edema, and manifest single cell necrosis. There were also nuclear changes, marked proliferation of smooth endoplasmatic reticulum, increased amounts of intracellular lipid vacuoles, and a decrease in glycogen particles in hepatocytes. The kidney presented the major changes in the tubules and in the interstitial part. MTX and 7-OH-MTX acute toxicity may primarily be related to microvascular perturbation.
Fuskevåg
O M
OM
Department of Pharmacology, Institute of Medical Biology, University of Tromsø, Norway.
Kristiansen
C
C
Olsen
R
R
Aarbakke
J
J
Lindal
S
S
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000648:ultrastructure; D022781:Hepatocytes / Q000187:drug effects / Q000648:ultrastructure; D007668:Kidney / Q000098:blood supply* / Q000648:ultrastructure; D008099:Liver / Q000098:blood supply* / Q000648:ultrastructure; D008297:Male; D020714:Maximum Tolerated Dose; D008727:Methotrexate / Q000031:analogs & derivatives / Q000633:toxicity*; D008833:Microcirculation / Q000187:drug effects / Q000648:ultrastructure; D051381:Rats; D017208:Rats, Wistar
D000970:Antineoplastic Agents; C011864:7-hydroxymethotrexate; D008727:Methotrexate